CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
IPO Year: 2015
Exchange: NASDAQ
Website: cytomx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/28/2024 | $2.25 → $3.50 | Neutral → Overweight | Piper Sandler |
5/9/2024 | $8.00 | Neutral → Outperform | Wedbush |
5/6/2024 | $2.50 → $8.00 | Hold → Buy | Jefferies |
4/22/2024 | Underweight → Neutral | JP Morgan | |
11/14/2022 | $3.00 → $2.60 | Outperform → Market Perform | BMO Capital Markets |
7/7/2022 | $16.00 → $4.00 | Buy → Neutral | Mizuho |
7/7/2022 | $10.00 → $1.50 | Overweight → Neutral | Piper Sandler |
7/7/2022 | $12.00 → $2.00 | Buy → Hold | Jefferies |
7/7/2022 | $6.00 → $2.00 | Outperform → Neutral | Wedbush |
6/24/2022 | $9.00 | Outperform | BMO Capital Markets |
SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company's board of directors. "We are excited to welcome Zhen to our board," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "With his extensive experience and accomplishments in oncology, Zhen brings expertise that will help shape strategy across our multi-modality PROBODY® therapeutic pipeline as well as CytomX's continued growth an
SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer (CMO). In this role, Dr. Chu will oversee clinical development of the Company's diversified portfolio of Probody® therapeutic candidates. "Wayne brings to CytomX substantial experience in clinical development strategy in the oncology space," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. "His drug development experiences have contributed to multiple approvals and span therapeutic modalitie
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company's next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation. "I would like to express my s
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022. "It has been an honor to serve on the CytomX board since the company's founding," said Frederick W. Gluck. "With a deep and differentiated clinical pipeline, a world class team and strong partnerships, CytomX is well positioned to deliver on its vision of bringing safer and more effective therapies to cancer patients and I wish the company continued success in the years to come." Mr. Gluck has served as a me
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the appointment of Alan Ashworth, Ph.D., FRS, a world-renowned expert in cancer research and a global leader in cancer therapy development, to the company's board of directors. "It is a privilege to welcome Alan to our board," commented Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. "As a highly distinguished cancer researcher with a deep emp
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced the appointment of Mani Mohindru, PhD to the Company’s board of directors. Dr. Mohindru brings to CytomX deep and varied experience across the life sciences industry, with particular experience in finance and corporate strategy. “We are pleased to welcome Mani to CytomX’s board of directors,” commented Sean McCarthy, D.Phil., president, chief executive officer (CEO) and chairman of CytomX. “Mani brings a
SC 13G - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.
CytomX Therapeutics's (NYSE:CTMX) short percent of float has risen 143.23% since its last report. The company recently reported that it has 8.75 million shares sold short, which is 11.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short i
Piper Sandler analyst Joseph Catanzaro upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweight and raises the price target from $2.25 to $3.5.
Wednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity. As of April 16, 2024, data cutoff, the Phase 1 study enrolled 35 heavily pretreated patients with advanced metastatic solid tumor types. CX-904 demonstrated a favorable safety profile, supporting administration and monitoring enrolled patients in an outpatient setting. Eight patients had measurable tumor reduction at data cutoff, including 2 of 6 efficacy-evaluable patients (33%) with pancreatic cancer with confirmed partial responses. All six efficacy-evaluable patient
U.S. stocks traded higher toward the end of trading, with the Dow Jones index jumping over 200 points on Thursday. The Dow traded up 0.63% to 39,300.69 while the NASDAQ rose 0.18% to 16,331.58. The S&P 500 also rose, gaining, 0.32% to 5,204.48 . Check This Out: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday Leading and Lagging SectorsReal estate shares rose by 2% on Thursday. In trading on Thursday, information technology shares fell by 0.3%. Top Headline Roblox Corp (NYSE:RBLX) posted better-than-expected first-quarter financial results, but issued weak guidance. Roblox reported fiscal first-quarter 2024 bookings growth of 19% year-on-year to $92
Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duolingo reported quarterly earnings of 57 cents per share which beat the analyst consensus estimate of 27 cents by 111.11%. Quarterly sales came in at $167.6 million which beat the analyst consensus estimate of $165.677 million and is a 44.91% increase from the same period last year, according to data from Benzinga Pro. Duolingo sees second-quarter revenues of between $175 million and $177.5 million, versus the $176.9 million estimate and full-year 2024 revenues of between $726.5 million and $735.5 million, versus the $728.23 million estimate. Du
Gainers Embecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out today. Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 36.28% to $1.02. The market value of their outstanding shares is at $154.2 million. The company's, Q1 earnings came out yesterday. G1 Therapeutics (NASDAQ:GTHX) shares rose 35.08% to $5.79. The company's market cap stands at $302.9 million. Vaccinex (NASDAQ:VCNX) shares rose 31.75% to $7.51. The market value of their outstanding shares is at $11.8 million. Zai Lab (NASDAQ:ZLAB) stock increased by 25.28% to $20.76. The company's
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Thursday. The Dow traded up 0.48% to 39,244.53 while the NASDAQ rose 0.32% to 16,354.20. The S&P 500 also rose, gaining, 0.37% to 5,206.94 . Check This Out: Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday Leading and Lagging SectorsReal estate shares rose by 1.7% on Thursday. In trading on Thursday, information technology shares fell by 0.2%. Top Headline US Foods Holding Corp (NYSE:USFD) posted better-than-expected first-quarter financial results on Thursday. US Foods reported first-quarter FY24 sales growth of 4.8% year-on-year to $8.95 billion,
BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and raises the price target from $3.25 to $3.59.
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY® ADC, is ongoing. Study is currently enrolling third cohort with enrollment focused primarily in colorectal cancer (CRC); initial data anticipated in the first half of 2025 - - First clinical site active for Phase 1 study of CX-801, an interferon alpha-2b PROBODY® cytokine, as monotherapy and in combination with KEYTRUDA® in solid tumors; initial data anticipated in the second half of 2025 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 8, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 patients (33%) with a confirmed partial response and all 6 patients (100%) with disease control - - Preliminary pharmacokinetic and pharmacodynamic analyses are supportive of PROBODY® T-Cell Engager platform mechanism of action - - Dose escalation and optimization continue - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) --
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pembrolizumab) for evaluation in combination with CX-801. Initial data anticipated in 2025 - - Achieved $10 million of milestones under T-cell engaging bispecific collaboration with Astellas for p
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics,
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report full year 2023 financial results on Monday, March 11, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on track for year-end - - Updated CX-801 (conditionally activated interferon alpha-2b) preclinical data presented at SITC 2023; IND filing for CX-801 also on track for year-end - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today reported third quarter 202
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report third quarter financial results on Tuesday, November 7, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report second quarter financial results on Tuesday, August 8, 2023, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prio
EFFECT - CytomX Therapeutics, Inc. (0001501989) (Filer)
S-3 - CytomX Therapeutics, Inc. (0001501989) (Filer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
10-Q - CytomX Therapeutics, Inc. (0001501989) (Filer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)
10-Q - CytomX Therapeutics, Inc. (0001501989) (Filer)
DEFA14A - CytomX Therapeutics, Inc. (0001501989) (Filer)
Piper Sandler upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $3.50 from $2.25 previously
Wedbush upgraded CytomX Therapeutics from Neutral to Outperform and set a new price target of $8.00
Jefferies upgraded CytomX Therapeutics from Hold to Buy and set a new price target of $8.00 from $2.50 previously
JP Morgan upgraded CytomX Therapeutics from Underweight to Neutral
BMO Capital Markets downgraded CytomX Therapeutics from Outperform to Market Perform and set a new price target of $2.60 from $3.00 previously
Mizuho downgraded CytomX Therapeutics from Buy to Neutral and set a new price target of $4.00 from $16.00 previously
Piper Sandler downgraded CytomX Therapeutics from Overweight to Neutral and set a new price target of $1.50 from $10.00 previously
Jefferies downgraded CytomX Therapeutics from Buy to Hold and set a new price target of $2.00 from $12.00 previously
Wedbush downgraded CytomX Therapeutics from Outperform to Neutral and set a new price target of $2.00 from $6.00 previously
BMO Capital Markets initiated coverage of CytomX Therapeutics with a rating of Outperform and set a new price target of $9.00
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September. H.C. Wainwright 26th Annual Global Investment ConferenceDate: Wednesday, September 11, 2024 Formal Presentation: 12:30 p.m. ET Location: New York, NY 2024 Cantor Global Healthcare ConferenceDate: Thursday, September 19, 2024Fireside Chat: 9:45 a.m. ET Location: New York, NY Live webcasts of the H.C. Wainwright presentation and Cantor fireside chat will be available on the Events and Presentations page of CytomX's webs
- CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY® ADC, is ongoing. Study is currently enrolling third cohort with enrollment focused primarily in colorectal cancer (CRC); initial data anticipated in the first half of 2025 - - First clinical site active for Phase 1 study of CX-801, an interferon alpha-2b PROBODY® cytokine, as monotherapy and in combination with KEYTRUDA® in solid tumors; initial data anticipated in the second half of 2025 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter financial results on Thursday, August 8, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX Therapeu
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. "Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization," said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. "We are excited to announce this promotion, which is a reflection of Chris' financial acumen, strategic leadership and deep commitment to CytomX's mission." Mr. Ogden joined CytomX in August of 2021 as Vice
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 3, 2024 /PRNewswire/ -- USA News Group – Recognized as one of the most lethal cancers, researchers are striving to improve survival rates for pancreatic cancer patients by focusing on earlier detection. According to Johns Hopkins Medicine, up to 80% of patients are diagnosed at advanced stages, which are significantly harder to treat. A new study published in the journal Cell Genomics demonstrates that researchers have identified key protein biomarkers for early detection of pancreatic cancer. Analysts at Towards Healthcare project the pancreatic cancer market to grow at a rate of 13.7% CAGR, hitting US
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference. About CytomX TherapeuticsCytomX is a clinical-stage, oncology-fo
SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company's common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants. The stock options were granted pursuant to the Company's 2019 Employment Inducement Incentive Plan, which was approved by the Company's board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employ
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 /PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with 97% accuracy. According to Johns Hopkins Medicine, up to 10% of patients who receive an early diagnosis become disease-free after treatment, meaning the earlier it's detected, the better the patient's chances to survive. The American Cancer Society estimates that about 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer in the USA this year, projec
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 patients (33%) with a confirmed partial response and all 6 patients (100%) with disease control - - Preliminary pharmacokinetic and pharmacodynamic analyses are supportive of PROBODY® T-Cell Engager platform mechanism of action - - Dose escalation and optimization continue - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) --
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)
4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)